Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYEGRH)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-4 (IL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[2]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[3]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[4]
Tepoxalin	DMVS61L	Asthma	CA23	Phase 2	[5]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[6]
Pascolizumab	DMU3XJP	Asthma	CA23	Phase 2	[4]
PF-07264660	DM0GI2H	Atopic dermatitis	EA80	Phase 1	[7]
PF-07275315	DMHRVUY	Atopic dermatitis	EA80	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70.
2	Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
3	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
4	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
5	Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30.
6	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
7	Clinical pipeline report, company report or official report of Pfizer